A ‘TripAdvisor-style’ website that helps scientists choose the best small-molecule tools for their experiments has been greatly expanded to include expert reviews of hundreds of chemical probes that ...

Our group's aim is to improve the treatment and survival of children with neuroblastoma, medulloblastoma and rhabdomyosarcoma. The goal of our laboratory is to improve the treatment and survival of ...

"Search" is our twice-yearly newsletter to supporters. In our 50th edition of the Autumn Search issue, we look at the latest research news featuring a new breast cancer drug approval in the UK, for ...

Yildiz joined the ICR in September 2024 as a postdoctoral training fellow. Previously she completed her MPharm degree at Istanbul University, followed by an MSc degree in Organic Chemistry at the ...

Isaline joined the ICR in September 2024 as a Postdoctoral Training Fellow. She completed her master’s in chemical process engineering at CPE Lyon, France with an Erasmus year at University College of ...

Dr Caroline Furness is a Group Leader at the Institute of Cancer Research and a Consultant Paediatric/TYA Haematologist at the Royal Marsden Hospital. She specialises in the care of paediatric ...

Dr Furness completed her medical training at Cambridge and Oxford University and her PhD at the Institute of Cancer Research. She trained in clinical haematology at the Royal Marsden Hospital and ...

One year of treatment with the targeted drug olaparib improves long-term survival in women with high-risk, early-stage breast cancer with mutations in BRCA1 or BRCA2 genes, new results from a major ...

Sentinal4D, a spinout company from The Institute of Cancer Research, London, has been announced to the public – having closed its first round of funding and appointed its foundational leadership team.